Mark Samuels, CEO of the British Generic Manufacturers Association, has slammed the UK government after an extensive “Life Sciences Vision” strategy document published yesterday contained no measures geared towards the off-patent sector.
BGMA ‘Astonished’ By UK Government Snub
Country’s Life Sciences Vision ‘Entirely Ignores Our Industry’ Says BGMA Chief
The UK government’s new Life Sciences Vision “entirely ignores” the off-patent industry, representing an “astonishing” snub given the value of the sector to the NHS and its critical role in fighting the COVID-19 pandemic, according to BGMA chief Mark Samuels.
More from Policy & Regulation
• By
Off-patent drug trade groups expressed their concerns that personnel and expertise cuts will affect the agency’s ability to review and approve generics and biosimilars.
• By
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
• By
FDA staffing cuts are making negotiation preparations more difficult, but also could mean the result is a smaller user fee renewal package.
• By
The US FDA has deemed certain CRO Raptim Research’s in vitro bioequivalence studies as “not acceptable” and raised concerns over its in vivo study methods. Will other agencies follow suit?
More from Generics Bulletin
• By
Off-patent drug trade groups expressed their concerns that personnel and expertise cuts will affect the agency’s ability to review and approve generics and biosimilars.
• By
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
• By
FDA staffing cuts are making negotiation preparations more difficult, but also could mean the result is a smaller user fee renewal package.